H
H. Bryan Brewer
Researcher at MedStar Washington Hospital Center
Publications - 215
Citations - 61956
H. Bryan Brewer is an academic researcher from MedStar Washington Hospital Center. The author has contributed to research in topics: Cholesterol & Apolipoprotein B. The author has an hindex of 75, co-authored 215 publications receiving 60497 citations. Previous affiliations of H. Bryan Brewer include American College of Cardiology & MedStar Health.
Papers
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone +8 more
TL;DR: The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
Journal ArticleDOI
Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
TL;DR: Although ATP III identified CVD as the primary clinical outcome of the metabolic syndrome, most people with this syndrome have insulin resistance, which confers increased risk for type 2 diabetes, when diabetes becomes clinically apparent, CVD risk rises sharply.
Journal ArticleDOI
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
DeWitt S. Goodman,Stephen B. Hulley,Luther T. Clark,Clay Davis,Valentin Fuster,John C. LaRosa,Albert Oberman,Ernst J. Schaefer,Daniel Steinberg,W. Virgil Brown,Scott M. Grundy,Diane M. Becker,Edwin L. Bierman,Jacqueline Sooter-Bochenek,Rebecca M. Mullis,Neil J. Stone,Donald B. Hunninghake,Jacqueline M. Dunbar,Henry N. Ginsberg,D. Roger Illingworth,Harold C. Sadin,Gustav Schonfeld,James I. Cleeman,H. Bryan Brewer,Nancy D. Ernst,William T. Friedewald,Jeffrey M. Hoeg,Basil M. Rifkind,David L. Gordon +28 more
TL;DR: New guidelines for the treatment of high blood cholesterol in adults 20 years of age and over are provided and which patients should go on to have lipoprotein analysis, and which should receive cholesterol-lowering treatment on the basis of their low density lipop protein levels and status with respect to other coronary heart disease risk factors are detailed.
Journal ArticleDOI
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Philip J. Barter,H. Bryan Brewer,M. John Chapman,Charles H. Hennekens,Daniel J. Rader,Alan R. Tall +5 more
TL;DR: Small-molecule inhibitors of CETP have now been tested in human subjects and shown to increase the concentration of HDL cholesterol while decreasing that of LDL cholesterol and apoB, and test the hypothesis in randomized trials of humans that pharmacological inhibition of CETp retards the development of atherosclerosis.